Simplify Logo

Full-Time

Medical Director

Remote

Confirmed live in the last 24 hours

4D Molecular Therapeutics

4D Molecular Therapeutics

51-200 employees

Develops gene therapies for genetic diseases

Hardware
Biotechnology
Healthcare

Compensation Overview

$268k - $345kAnnually

Mid, Senior

United States

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Communications
Public Speaking
Data Analysis
Requirements
  • Medical Degree (M.D.)
  • Residency training in Ophthalmology
  • Board certification a plus
  • 3+ years of clinical ophthalmology research in the biopharmaceutical industry
  • Experience with retina clinical trials
  • Experience with gene therapy a plus
  • Experience in other phases (Phase 1, 2, 4) of clinical research a plus
  • Experience writing clinical research protocols and acting as a medical monitor
  • Experience in data analysis, data interpretation, and medical writing
  • Effective written and verbal communication skills, including public speaking
  • Knowledge of ICH-GCP and FDA regulatory guidelines.
  • Knowledge of international regulatory guidelines a plus
  • Ability to travel 15% (3 days/month)
  • Remote/hybrid acceptable but Local/Hybrid preferred
Responsibilities
  • Provides clinical leadership to multidisciplinary study execution teams drawn from clinical operations, clinical science, biometrics, regulatory affairs, CMC, pharm/tox, drug safety, commercial, and alliance partners
  • Has lead accountability on the study teams for delivery of study protocols, study conduct, and study readouts
  • Serves as medical monitor on clinical studies.
  • Organizes and leads scientific advisory board meetings. Interacts with external experts and stakeholders to gather input.
  • Serves as the primary clinical author of development plans, study protocols, amendments, ICFs, IBs, INDs, annual reports, CSRs, regulatory submissions / correspondence, and project-related documents. Accountable for the accuracy of all medical content of such documents.
  • Works with the research organization and the portfolio management team to identify and support new project opportunities.
  • Collaborates to identify program risks, and to create and implement mitigation strategies
  • Other duties as assigned
4D Molecular Therapeutics

4D Molecular Therapeutics

View

4D Molecular Therapeutics develops gene therapies aimed at treating serious genetic diseases by delivering specific genetic material to patients' cells. The company utilizes a unique technology called Therapeutic Vector Evolution to create adeno-associated virus (AAV) vectors, which act as delivery vehicles for therapeutic genes targeting affected cells. Unlike many competitors, 4DMT focuses on precision medicine for genetic disorders, including cystic fibrosis, and emphasizes rigorous research and clinical trials to ensure the safety and effectiveness of its therapies. The company's goal is to commercialize these gene therapies through direct sales or partnerships with larger pharmaceutical firms, while also securing funding to support its development efforts.

Company Stage

IPO

Total Funding

$595M

Headquarters

Emeryville, California

Founded

2013

Growth & Insights
Headcount

6 month growth

13%

1 year growth

20%

2 year growth

49%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful clinical trials, such as the positive interim data from the Phase 1/2 AEROW trial, bolster confidence in 4DMT's therapeutic pipeline.
  • The recent $75 million Series C financing provides substantial capital to advance R&D and clinical programs.
  • The appointment of experienced executives, like Uneek Mehra as Chief Financial and Business Officer, strengthens the company's leadership team.

What critics are saying

  • The biopharmaceutical market is highly competitive, with numerous companies vying to develop similar gene therapies.
  • Regulatory hurdles and clinical trial setbacks, such as the initial clinical hold on 4D-310, can delay product development and commercialization.

What makes 4D Molecular Therapeutics unique

  • 4DMT leverages its proprietary 'Therapeutic Vector Evolution' technology to create advanced AAV vectors, setting it apart from competitors in the gene therapy space.
  • The company's focus on aerosolized genetic medicines, such as 4D-710 for cystic fibrosis, highlights its innovative approach to gene delivery.
  • Strategic partnerships, like the $962M deal with Astellas Pharma, underscore 4DMT's ability to attract significant investment and collaboration opportunities.